Regeneron Pharmaceuticals: Ubamatamab Shows 73% Objective Response Rate in LGSOC Patients

Regeneron Pharmaceuticals announced that its drug Ubamatamab demonstrated a 73% objective response rate and an 11-month median progression-free survival in patients with LGSOC.